Update on antibacterial resistance in low-income countries: Factors favoring the emergence of resistance

Open Infectious Diseases Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 38-54

  Vila, Jordi ^a   Pal, Tibor ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Antimicrobial agents; Developing countries; Enteric pathogens; M. tuberculosis; Resistance; S. aureus; S. pneumoniae

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CEFEPIME; CEFIXIME; CEFOPERAZONE; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG;

ANIMAL HEALTH; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CAMPYLOBACTER; CAMPYLOBACTER ENTERITIS; DEVELOPING COUNTRY; DRUG DOSE INCREASE; DRUG POTENCY; DYSENTERY; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; GONORRHEA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTIOUS DIARRHEA; LABORATORY DIAGNOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SALMONELLA; SHIGELLA; SOCIOECONOMICS;

MYCOBACTERIUM TUBERCULOSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 77958523511     PISSN: None     EISSN: 18742793     Source Type: Journal    
DOI: 10.2174/1874279301004020038     Document Type: Article

References (220)

1. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11: 142-201.
2. Vargas M, Gascón J, Gallardo F, et al. Prevalence of diarrheagenic Escherichia coli strains detected by PCR in patients with travelers' diarrhea. Clin Microbiol Infect 1998; 4: 682-8.
3. Sire JM, Nabeth P, Perrier-Gros-Calude JD, et al. Antimicrobial resistance in outpatient Escherichi coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries 2007; 1: 263-8.
4. Hima-Lerible H, Ménard D, Talarmin A. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic. J Antimicrob Chemother 2003; 51: 192-4.
5. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries 2008; 2: 354-8.
6. Randrianirina F, Soares JL, Carod JF, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother 2007; 59: 309.
7. Matute AJ, Hak E, Schurink CAM, et al. Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua. Int J Antimicrob Agents 2004; 23: 506-9.
8. Ahmed AA, Osman H, Mansour AM, et al. Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in the Sudan. Am J Trop Med Hyg 2000; 63: 259-63.
9. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum -lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005; 52: 323-9.
10. Qadri F, Svennerholm AM, Faruque ASG, Sack RB. Enterotoxigenic Escherichia coli in developing countries: Epidemiology, microbiology, clinical features, treatment and prevention. Clin Microbiol Rev 2005; 18: 465-83.
11. Rao MR, Abu-Elyazeed R, Savarino SJ, et al. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol 2003; 41: 4862-4.
12. Vila J, Vargas M, Casals C, et al. Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania. Antimicrob Agents Chemother 1999; 43: 3022-4.
13. Rowland MG. The Gambia and Bangladesh-the seasons and diarrhoea. Dialogue Diarrhoea 1986; (26): 3.
14. Echevarria P, Verhaert L, Ulyangco CV, et al. Antimicrobial resistance and enterotoxin production among isolates of Escherichia coli in the Far East. Lancet 1978; ii:589-92.
15. Martínez L, Arenas MM, Montes MY, Martínez LJ, Baca BE. Antibiotic resistance and plasmid pattern of enterotoxigenic ST-a strains of Escherichia coli isolated in Puebla, Mexico. Can J Microbiol 1987; 33: 816-9.
16. Isenbarger DW, Hoge CW, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002; 8: 175-80.
17. Mendez-Arancibia E, Pitart C, Ruiz J, Marco F, Gascón J, Vila J. Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother 2009; 64: 343-7.
18. Nataro JP, Kaper JB, Robins-Browne R et al. Pattterns of adherence of diarrheagenic Escherichia coli to Hep-2 cells. Pediatr Infect Dis J 1987; 6: 829-31.
19. Mendez-Arancibia E, Vargas M, Soto S, et al. Prevalence of different virulence factors and biofilm production in enteroaggregative Escherichia coli isolates causing diarrhea in children in Ifakara (Tanzania). Am J Trop Med Hyg 2008; 78: 985-9.
20. Vargas M, Gascón J, Casals C, et al. Etiology of diarrhea in children less than five years of age in Ifakara, Tanzania. Am J Trop Med Hyg 2004; 70: 536-9.
21. Sang WK, Oundo JO, Mwituria JK, et al. Multidrug-resistant enteroaggregative Escherichia coli associated with persistent diarrhea in Kenyan children. Emerg Infect Dis 1997; 3: 373-4.
22. Okeke IN, Lamikanra A, Czeczulin J, et al. Heterogeneous virulence of enteroaggregative Escherichia coli strains isolated from children in Southwest Nigeria. J Infect Dis 2000; 181: 252-60.
23. Yamamoto T, Echeverria P, Yokota T. Drug resistance and adherence to human intestines of enteroaggregative Escherichia coli. J Infect Dis 1992; 165: 744-9.
24. Sonnevend A, Al Dhaheri K, Mag T, et al. T. CTX-M-15 producing multidrug resistant enteroaggregative Escherichia coli in the United Arabs Emirates. Clin Microbial Infect 2006; 12: 582-5.
25. Torres ME, Pirez MC, Schelotto F, et al. Etiology of children's diarrhea in Montevideo, Uruguay: associated pathogens and unusual isolates. J Clin Microbiol 2001; 39: 2134-9.
26. Ekdahl K, Andersson Y. The epidemiology of travel-associated shigellosis - regional risks, seasonality and serogroups. J Infect 2005; 51: 222-9.
27. Lima AAM, Lima NL, Pinho MCN, et al. High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in Northeastern Brazil during the period 1988 to 1993. Antimicrob Agents Chemother 1995; 39: 256-9.
28. Dutta S, Sinha T, Dutta P. Serotypes and antimicrobial susceptibility patterns of Shigella species isolated from children in Calcutta, India. Eur J Clin Microbiol Infect Dis 1998; 17: 298-9.
29. Tjaniadi P, Lesmana M, Subekti D, et al. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. Am J Trop Med Hyg 2003; 68: 666-70.
30. Brooks JT, Chieng JB, Kumar L, et al. Surveillance for bacterial diarrhea and antimicrobial resistance in rural Western Kenya, 1997-2003. Clin Infect Dis 2006; 43: 393-401.
31. Bogaerts J, Verhaegen J, Munyabikali JP, et al. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance. Diagn Microbiol Infect Dis 1997; 28: 165-71.
32. Navia MM, Capitano L, Ruiz J, et al. Typing and characterization of mechanisms of resistance of Shigella spp isolated from feces of children under 5 years of age from Ifakara, Tanzania. J Clin Microbiol 1999; 37: 3113-7.
33. Nguyen TV, Le PV, Weintraub A. Antibiotic resistance in diarrheagenic Escherichia coli and Shigella strains isolated from children in Hanoi, Vietnam. Antimicrob Agents Chemother 2005; 49: 816-9.
34. Lee JC, Oh JY, Kim KS, et al. Antimicrobial resistance of Shigella sonnei in Korea during the last two decades. APMIS 2001; 109: 228-34.
35. Ries AA, Wells JG, Olivola MD, et al. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J Infect Dis 1994; 169: 1035-41.
36. Mensa L, Marco F, Vila J, Gascón J, Ruiz J. Quinolone resistance among Shigella spp. Isolated from travellers returning from India. Clin Microbiol Infect 2008; 14: 279-81.
37. Fàbrega A, du Merle L, Le Bouguénec C, Jimenez de Anta MT, Vila J. Repression of invasion genes and decreased invasion in a high-level fluoroquinolone-resistant Salmonella Typhimurium mutant. PLoS One 2009: 4: e8029.
38. Cook E. Salmonella species (including typhoid fever). In Mandell GL, Douglas RG, Bennet JE, Eds. Principles and practices of infectious diseases. Churchill Livingston: New York 1990; pp. 1700-15.
39. Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8(Suppl 2): S172-81.
40. Peirano G, Agerso Y, Aarestrup FM, Falavina dos Reis EM, dos Prazeres Rodriguez D. Ocurrence of integrons and antimicrobial resistance genes among Salmonella enterica from Brazil. J Antimicrob Chemother 2006; 58: 305-9.
41. Ammari S, Laglaoui A, En-nanei L, et al. Isolation, drug resistance and molecular characterization of Salmonella isolates in northern Morocco. J Infect Dev Ctries 2009; 3: 41-9.
42. Lee HY, Su LH, Tsai MH, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009; 53: 2696-9.
43. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986; 109: 355-60.
44. Trofa KAF, Thomas RJ. Use of azithromycin for the treatment of Campylobacter enteritis in travellers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536-41.
45. Goosens H, DeMol P, Coignan H et al. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU 28965 (a new macrolide) and other agents against enteropathogens. Antimicrob Agents Chemother 1985; 27: 388-92.
46. Ruiz J, Marco F, Oliveira I, Gascón J, Vila J. trends in antimicrobial resistance in Campylobacter spp. Causing traveler's diarrhea. APMIS 2007; 115: 218-24.
47. Galanis E. Campylobacter and bacterial gastroenteritis. Can Med Assoc J 2007; 177: 570-1.
48. Dalsgaard A, Forslund A, Sandvang D, Arntzen L, Keddy K. Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multi-drug resistant, contain the sxt element and the aadA2 gene located on class 1 integron. J Antimicrob Chemother 2001; 48: 827-38.
49. Das S, Saha R, Kaur IR. Trend of antibiotic resistance of V. cholerae strains from East Delhi. Indian J Med Res 2008; 127: 478-82.
50. Garg P, Sinha S, Chakraborty R, et al. Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. Antimicrob Agents Chemother 2001; 45: 1605-6.
51. Figueras MJ. Clinical relevance of Aeromonas. Rev Med Microbiol 2005; 16: 145-53.
52. Taneja N, Khurana S, Trehan A, Marwaha RK, Sharma M. Na outbreak of hospital acquired diarrhea due to Aeromonas sobria. Indian Pediatr 2004; 41: 912-6.
53. Ghenghesh KS, Ahmed SF, El-Khalek RA, Al-Gendy A, Klena J. Aeromonas-associated infections in developing countries. J Infect Dev Ctries 2008; 2: 81-98.
54. Stock I, Wiedemann B. Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. J Antimicrob Chemother 2001; 48: 803-11.
55. Lagamayo EN. Antimicrobial resistance in major pathogens of hospital-acquired pneumonia in Asian countries. Am J Infect Control 2008; 36: S101-8.
56. Ndip RN, Dilonga HM, Ndip LM, Akoachere JFK, Akeujit N. P. aeruginosa isolates recovered from clinical and environmental samples in Nuea, Cameroon: Current status on biotyping and antibiogram. Trop Med Int Health 2005; 10: 74-81.
57. Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among P. aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY antimicrobial surveillance program (1997-2001). J Antimicrob Chemother 2003; 52: 140-1.
58. Lee K, Park KH, Jeong SH, et al. Further increase of vancomycin- resistant Enterococcus faecium, amikacin- and fluoroquinolone- resistan Klebsiella pneumoniae, and imipenem-resistant Acinetobacter species in Korea: 2003 KONSAR Surveillance. Yonsei Med J 2006; 47: 43-54.
59. Singh AK, Sen MR, Anapurba S, Bhattacharya P. Antibiotic sensitivity pattern of the bacteria isolated from nosocomial infections in ICU. J Commun Dis 2002; 34: 257-63.
60. Pachon J, Vila J. Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Invest Drugs 2009; 10: 150-6.
61. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65(2): 233-8.
62. O'Brien KL, Wolfson LJ, Watt JP, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
63. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451-65.
64. Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009; 27: 3802-10.
65. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA: CLSI 2008.
66. Hsieh YC, Lin PY, Chiu CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009; 27: 5513-8.
67. Felmingham D, Cantón R, Jenkins SG. Regional trends in betalactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55: 111-8.
68. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008; 120(Suppl 1): 16-24.
69. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 2004; 10: 645-51.
70. Camargos P, Fischer GB, Mocelin H, Dias C, Ruvinsky R. Penicillin resistanceand serotyping of Streptococcus pneumoniae in Latin America. Paediatr Respir Rev 2006; 7: 209-14.
71. Vlieghe E, Phoba MF, Tamfun JJ, Jacobs J. Antibiotic resistance among bacterial pathogens in Central Africa: a review of the published literature between 1955 and 2008. Int J Antimicrob Agents 2009; 34: 295-303.
72. Mudhune S, Wamae M. Network Surveillance for Pneumococcal Disease in the East African Region. Report on invasive disease and meningitis due to Haemophilus influenzae and Streptococcus pneumonia from the Network for Surveillance of Pneumococcal Disease in the East African Region. Clin Infect Dis 2009; 48(Suppl 2): S147-52.
73. Hill PC, Onyeama CO, Ikumapayi UN, et al. Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infect Dis 2007; 7: 2.
74. Borg MA, Tiemersma E, Scicluna E, et al. Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 2009; 15: 232-7.
75. Memish ZA, Balkhy HH, Shibl AM, Barrozo CP, Gray GC. Streptococcus pneumoniae in Saudi Arabia: antibiotic resistance and serotypes of recent clinical isolates. Int J Antimicrob Agents 2004; 23: 32-8
76. Senok A, Al-Zarouni M, Al-Najjar J, Nublusi A, Panigrahi D. Antimicrobial resistance among Streptococcus pneumoniae and Haemophilus influenzae isolates in the United Arab Emirates: 2004-2006. J Infect Dev Ctries 2007; 1: 296-302.
77. Shibl A, Memish Z, Pelton S. Epidemiology of invasive pneumococcal disease in the Arabian Peninsula and Egypt. Int J Antimicrob Agents 2009; 33: 410. e1-9.
78. Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48: 2101-7.
79. Liu Y, Wang H, Chen M, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 2008; 61: 256-63.
80. Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009; 27: 7282-91
81. Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int J Antimicrob Agents 2008; 31: 245-9.
82. Wolter N, von Gottberg A, du Plessis M, de Gouveia L, Klugman KP. Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Int J Antimicrob Agents 2008; 32: 62-7.
83. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008; 8: 785-95.
84. Picazo JJ. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Clin Microbiol Infect 2009; 15(Suppl 3): 4-6.
85. Kyaw MH, Lynfield R, Schaffner W, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 1455-63.
86. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; 4: CD004977.
87. World Health Organization Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007; 82: 93-104.
88. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Children who Participated in a 9-valent Pneumococcal Conjugate Vaccine Trial and in Their Younger Siblings. Pediatr Infect Dis J 2009; 28: 990-5.
89. Hsieh YC, Wang JT, Lee WS, et al. Serotype competence and penicillin resistance in Streptococcus pneumoniae. Emerg Infect Dis 2006; 12: 1709-14.
90. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15(Suppl 3): 7-11.
91. Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008; 14: 275-81.
92. Antonio M, Dada-Adegbola H, Biney E, et al. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis 2008; 8: 81.
93. Arifeen SE, Saha SK, Rahman S, et al. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance. Clin Infect Dis 2009; 48(Suppl 2): S103-S13.
94. Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium Members. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36: 627-37.
95. Sood S, Malhotra M, Das BK, Kapil A. Enterococcal infections & antimicrobial resistance. Indian J Med Res 2008; 128: 111-21.
96. Ergani-Ozcan A, Naas T, Baysan BO, et al. Nosocomial outbreak of vancomycin-resistant Enterococcus faecium in a paediatric unit at a Turkish university hospital. J Antimicrob Chemother 2008; 61: 1033-9.
97. Zubaidah AW, Ariza A, Azmi S. Hospital-acquired vancomycin- resistant enterococci: now appearing in Kuala Lumpur Hospital. Med J Malaysia 2006; 61: 487-9.
98. Ghoshal U, Garg A, Tiwari DP, Ayyagari A. Emerging vancomycin resistance in enterococci in India. Indian J Pathol Microbiol 2006; 49: 620-2.
99. Jeric PE, Azpiroz A, Lopardo H, Centrón D. Survey of molecular determinants in Gram-positive cocci isolated from hospital settings in Argentina. J Infect Dev Ctries 2007; 1: 275-83.
100. Cuellar-Rodríguez J, Galindo-Fraga A, Guevara V, et al. Vancomycin-resistant enterococci, Mexico City. Emerg Infect Dis 2007; 13: 798-9.
101. McCarthy KM, Van Nierop W, Duse A, et al. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000; 44: 294-300.
102. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 2007; 30: 143-9.
103. Emaneini M, Aligholi M, Aminshahi M. Characterization of glycopeptides, aminoglycosides and macrolide resistance among Enterococcus faecalis and Enterococcus faecium isolates from hospitals in Tehran. Pol J Microbiol 2008; 57: 173-8.
104. Rattanaumpawan P, Thamlikitkul V, Chokepaibulkit K, Lohsiriwat D, Aswapokee N. Vancomycin overuse in Siriraj Hospital. J Med Assoc Thai 2006; 89(Suppl 5): S125-S32.
105. McCarthy KM, Van Nierop W, Duse A, et al. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000; 44: 294-300.
106. Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11: 821-8.
107. Zhu X, Zheng B, Wang S, et al. Molecular characterisation of outbreak-related strains of vancomycin-resistant Enterococcus faecium from an intensive care unit in Beijing, China. J Hosp Infect 2009; 72: 147-54.
108. Shin JW, Yong D, Kim MS, et al. Sudden increase of vancomycin- resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003; 9: 62-7.
109. Singh BR. Prevalence of vancomycin resistance and multiple drug resistance in enterococci in equids in North India. J Infect Dev Ctries 2009; 3: 498-503.
110. Hahn W, Morley CP, Morrow C, Epling JW. The effect of media attention on concern for and medical management of methicillin- resistant Staphylococcus aureus: a multimethod study. J Public Health Manage Pract 2009; 15: 150-9.
111. Nickerson EK, Hongsuwan M, Limmathurotsakul D, et al. Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS One 2009; 4: e4308.
112. Nickerson EK, West TE, Day NP, Peacock SJ. Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia. Lancet Infect Dis 2009; 9: 130-5.
113. Randrianirina F, Soares JL, Ratsima E, et al. In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar. Ann Clin Microbiol Antimicrob 2007; 6: 5.
114. Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT. Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal Ed 2005; 90: F220-4.
115. Osrin D, Vergnano S, Costello A. Serious bacterial infections in newborn infants in developing countries. Curr Opin Infect Dis 2004; 17: 217-24.
116. Kesah C, Ben Redjeb S, Odugbemi TO, et al. Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin Microbiol Infect 2003; 9: 153-6.
117. Orrett FA, Land M. Methicillin-resistant Staphylococcus aureus prevalence: current susceptibility patterns in Trinidad. BMC Infect Dis 2006; 6: 83.
118. Mehndiratta PL, Vidhani S, Mathur MD. A study on Staphylococcus aureus strains submitted to a reference laboratory. Indian J Med Res 2001; 114: 90-4.
119. Anapurba S, Sen MR. Prevalence of methicillin resistant Staphylococcus aureus in a tertiary referral hospital in eastern Uttar Pradesh. Ind J Med Microbiol 2003; 21: 49-51.
120. Khan AU, Sultan A, Tyagi A, et al. Amplification of mecA gene in multi-drug resistant Staphylococcus aureus strains from hospital personnel. BMC Infect Dis 2007; 1: 289-95.
121. Ko KS, Lee YJ, Suh JY, et al. Distribution of major genotypes among methicillin-resistant Staphylococcus aureus clones in Asian countries. J Clin Microbiol 2005; 43: 421-6.
122. Chongtrakool, P, Ito T, Ma XX, et al. Staphylococcal cassette chromosome mec (SCCmec) typing of methicillinresistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother 2006; 50: 1001-12.
123. Witte W, Cuny C, Klare I, Nübel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int J Med Microbiol 2008; 298: 365-77.
124. Shittu A, Nübel U, Udo E, Lin J, Gaogakwe S. Characterization of meticillin-resistant Staphylococcus aureus isolates from hospitals in KwaZulu-Natal province, Republic of South Africa. J Med Microbiol 2009; 58: 1219-26.
125. Gadepalli R, Dhawan B, Kapil A, et al. Clinical and molecular characteristics of nosocomial meticillin-resistant Staphylococcus aureus skin and soft tissue isolates from three Indian hospitals. 2009; 73: 253-63.
126. Nickerson EK, Wuthiekanun V, Day NP, Chaowagul W, Peacock SJ. Meticillin-resistant Staphylococcus aureus in rural Asia. Lancet Infect Dis 2006; 6: 70-1.
127. Nickerson EK, Wuthiekanun V, Wongsuvan G, et al. Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One 2009b; 4(8): e6512.
128. Thaver D, Ali SA, Zaidi AK. Antimicrobial resistance among neonatal pathogens in developing countries. Pediatr Infect Dis J 2009; 28(1 Suppl): S19-21.
129. Brown PD, Ngeno C. Antimicrobial resistance in clinical isolates of Staphylococcus aureus from hospital and community sources in southern Jamaica. Int J Infect Dis 2007; 11: 220-5.
130. Onipede AO, Onayade AA, Elusiyan JB, et al. Invasive bacteria isolates from children with severe infections in a Nigerian hospital. J Infect Dev Ctries 2009; 3: 429-36.
131. Nagaraju U, Bhat G, Kuruvila M, Pai GS, Jayalakshmi Babu RP. Methicillin-resistant Staphylococcus aureus in community-acquired pyoderma. Int J Dermatol 2004; 43: 412-14.
132. Baranwal AK, Singh M, Marwaha RK, Kumar L. Empyema thoracis: a 10-year comparative review of hospitalised children from south Asia. Arch Dis Child 2003; 88: 1009-14.
133. Krishna BV, Patil AB, Chandrasekhar MR. Community-acquired methicillin-resistant Staphylococcus aureus infections in a south Indian city. Southeast Asian J Trop Med Public Health 2004; 35: 371-74.
134. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46(Suppl 5): S360-S7.
135. Orrett FA. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report. Jpn J Infect Dis 2008; 61: 107-10.
136. Udo EE, Jacob LE, Mathew B. The spread of a mupirocin- resistant/methicillin-resistant Staphylococcus aureus clone in Kuwait hospitals. Acta Trop 2001; 80: 155-61.
137. Song JH, Hiramatsu K, Suh JY, et al. Asian Network for Surveillance of Resistant Pathogens Study Group. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48: 4926-8.
138. Sun W, Chen H, Liu Y, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob Agents Chemother 2009; 53: 3642-9.
139. Lulitanond A, Engchanil C, Chaimanee P, Vorachit M, Ito T, Hiramatsu K. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J Clin Microbiol 2009; 47: 2311-6.
140. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6: 156.
141. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366: 144-50.
142. Lewis RF, Kisakye A, Gessner BD, et al. A. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 2008; 86: 292-301.
143. Watt JP, Wolfson LJ, O'Brien KL, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374: 903-11.
144. Reid AJ, Simpson IN, Harper PB, Amyes SG. Ampicillin resistance in Haemophilus influenzae: identification of resistance mechanisms. J Antimicrob Chemother 1987; 20: 645-56.
145. Vega R, Sadoff HL, Patterson MJ. Mechanisms of ampicillin resistance in Haemophilus influenzae type B. Antimicrob Agents Chemother 1976; 9: 164-8.
146. Srifuengfung S, Chayakulkeeree M, Chokephaibulkit K, Tribuddharat C. Five-year study of antimicrobial susceptibility and beta- lactamase production in Haemophilus influenzae. Southeast Asian J Trop Med Public Health 2007; 38: 732-6.
147. Kunthalert D, Thunyathada PK, Pruksakorn S. Phenotypic and genetic characterizations of nontypeable Haemophilus influenzae isolates in a hospital in Thailand. J Infect 2009; 59: 293-6.
148. Youssef FG, El-Sakka H, Azab A, et al. Antimicrobial susceptibility profiles, and mortality associated with bacterial meningitis among children in Egypt. Ann Epidemiol 2004; 14: 44-8.
149. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 2006; 56: 427-36.
150. Scott JA, Mwarumba S, Ngetsa C, et al. Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenzae obtained from children admitted to a hospital in Kilifi, Kenya, from 1994 to 2002. Antimicrob Agents Chemother 2005; 49: 3021-4.
151. Mendelman PM, Chaffin DO, Kalaitzoglou G. Penicillin-binding proteins and ampicillin resistance in Haemophilus influenzae. J Antimicrob Chemother 1990; 25: 525-34.
152. Hasegawa K, Chiba N, Kobayashi R, et al. Rapidly increasing prevalence of beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis. Antimicrob Agents Chemother 2004; 48: 1509-14.
153. Hasegawa K, Yamamoto K, Chiba N, et al. Diversity of ampicillin- resistance genes in Haemophilus influenzae in Japan and the United States. Microbiol Drug Resist 2003; 9: 39-46.
154. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada. Curr Med Res Opin 2008; 24: 2853-61.
155. Niki Y, Hanaki H, Yagisawa M, et al. Japanese Society of Chemotherapy. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. J Infect Chemother 2008; 14: 279-90.
156. Gotoh K, Qin L, Watanabe K, et al. Prevalence of Haemophilus influenza with resistant genes isolated from young children with acute lower respiratory tract infections in Nha Trang, Vietnam. J Infect Chemother 2008; 14: 349-53.
157. Jain A, Kumar P, Agarwal SK. High nasopharyngeal carriage of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae in north Indian school-going children. J Infect Chemother 2008; 14: 72-4.
158. Wang SR, Lo WT, Chou CY, et al. Low rate of nasopharyngeal carriage and high rate of ampicillin resistance for Haemophilus influenzae among healthy children younger than 5 years old in northern Taiwan. J Microbiol Immunol Infect 2008; 41: 32-40.
159. Jean SS, Hsueh PR, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 2009; 28: 1013-7.
160. Brook I. Current issues in the management of acute bacterial sinusitis in children. Int J Pediatr Otorhinolaryngol 2007; 71: 1653-61.
161. Yamanaka N, Hotomi M, Billal DS. Clinical bacteriology and immunology in acute otitis media in children. J Infect Chemother 2008; 14: 180-7.
162. WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates WHO. Geneva 2001.
163. Gerbase AC, Rowley JT, Heymann DH, Berkley SF, Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998; 74(Suppl 1): S12-6.
164. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148: 606-13.
165. Iverson CJ, Wang SA, Lee MV, et al. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex Transm Dis 2004; 31: 702-8.
166. Su X, Jiang F, Qimuge Dai X, Sun H, Ye S. Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999-2006. Sex Transm Dis 2007; 34: 995-9.
167. Sihavong A, Phouthavane T, Lundborg CS, Sayabounthavong K, Syhakhang L, Wahlström R. Reproductive tract infections among women attending a gynecology outpatient department in Vientiane, Lao PDR. Sex Transm Dis 2007; 34: 791-5.
168. Bala M, Ray K, Gupta SM, Muralidhar S, Jain RK. Changing trends of antimicrobial susceptibility patterns of Neisseria gonorrhoeae in India and the emergence of ceftriaxone less susceptible N. gonorrhoeae strains. J Antimicrob Chemother 2007; 60: 582-6.
169. Bala M, Jain RK, Ray K. Antimicrobial susceptibility profile of resistance phenotypes of Neisseria gonorrheae in India. Sex Transm Dis 2008; 35: 588-91.
170. De Jongh M, Dangor Y, Adam A, Hoosen AA. Gonococcal resistance: evolving from penicillin, tetracycline to the quinolones in South Africa -- implications for treatment guidelines. Int J STD AIDS 2007; 18: 697-9.
171. Moodley P, Martin IM, Pillay K, Ison CA, Sturm AW. Molecular epidemiology of recently emergent ciprofloxacin-resistant Neisseria gonorrhoeae in South Africa. Sex Transm Dis 2006; 33: 357-60.
172. Cao V, Ratsima E, Van Tri D, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in 2004-2006 in Bangui, Central African Republic; Yaoundé, Cameroon; Antananarivo, Madagascar; and Ho Chi Minh Ville and Nha Trang, Vietnam. Sex Transm Dis 2008; 35: 941-5.
173. Apalata T, Zimba TF, Sturm WA, Moodley P. Antimicrobial susceptibility profile of Neisseria gonorrhoeae isolated from patients attending a STD facility in Maputo, Mozambique. Sex Transm Dis 2009; 36: 341-3.
174. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821-34.
175. Jahan Y, Begum K, Murshed M, Kabir A, Begum K. Multiple drug resistant Neisseria gonorrhoeae among females of high risk behaviour in Dhaka city. J Prev Soc Med 1999; 18: 46-51.
176. Tapsall JW. Implications of current recommendations for third- generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009; 85: 256-8.
177. CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections. MMWR 2007; 56: 332-6.
178. Tapsall JW. Implications of current recommendations for third- generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009; 85: 256-8.
179. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13: 1275-7.
180. WHO Western Pacific Gonococccal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun Dis Intell 2008; 32: 48-51.
181. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009; 22: 87-91.
182. Sosa J, Ramirez-Arcos S, Ruben M, et al. High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998. Sex Transm Dis 2003; 30: 443-8.
183. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317: 272-8.
184. WHO. WHO Report 2009. Global Tuberculosis Control. Epidemiology, Strategy, Financing. Geneva 2009.
185. Doomsday DC. Postponed-Preventing and reversing epidemics of drug resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-7.
186. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9: 19-30.
187. CDC. Notice to Readers: Revised Definition of Extensively Drug- Resistant Tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
188. Wright A, Zignol M, Van Deun A, et al. Global Project on Anti- Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-73.
189. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-7.
190. Borgdorff MW, Small PM. Scratching the surface of ignorance on MDR tuberculosis. Lancet 2009; 373: 1822-4.
191. Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol 2008; 53: 145-50.
192. WHO 2000. Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-Resistant Tuberculosis (MDRTB). Geneva, Switzerland 2000; WHO/CDS/TB/2000.278.
193. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
194. Stroud LA, Tokars JI, Grieco MH, et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995; 16: 141-7.
195. Basu S, Andrews JR, Poolman EM, et al. South African district hospitals: an epidemiological modelling study. Lancet 2007; 370: 1500-7.
196. Planta MB. The role of poverty in antimicrobial resistance. J Am Board Fam Med 2007; 20: 533-9.
197. Land T. Combating counterfeit drugs. Nature 1992; 355: 192.
198. McGregor A. Counterfeit drugs flood developing world. Lancet 1997; 350: 1690.
199. Pecoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: a lost battle? J Am Med Assoc 1999; 281: 361-7.
200. Okeke I, Lamikanra A. Quality and bioavailability of tetracycline capsules in a Nigerian semi-urban community. Int J Antimicrob Agents 1995; 5: 245-50.
201. Agom JK, Akannii AO, Dawodu TO. Quality of ampicillin/cloxacillin preparations on the Nigerian market. Niger J Pharmacol 1990; 21: 36-8.
202. Gustafsson LL, Wide K. Marketing of obsolete antibiotics in Central America. Lancet 1981; 1: 31-3.
203. Ali HM, Homeida MM, Abdeen MA. Drug dumping in donations to Sudan. Lancet 1988; 333: 538-9.
204. Kigotho AW. Kenya's government tackles influx of sub-standard drugs. Lancet 1997; 350: 1690.
205. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999; 5: 18-27.
206. Hogerzel HV, Battersby A, Srdanovic V, Stjernstrom NE. Stability of essential drugs during shipment to the tropics. Br Med J 1992; 304: 210-2.
207. Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997; 2: 839-45.
208. Ballereau F, Prazuck T, Schrive I, et al. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina-Faso. Am J Trop Med Hyg 1997; 57: 31-6.
209. Lansang MA, Lucas-Aquino R, Tupasi TE, et al. Purchase of antibiotics without prescription in Manila, Philippines. Inappropriate choices and doses. J Clin Epidemiol 1990; 43: 61-7.
210. Guyon AB, Barman A, Ahmed JU, et al. A baseline survey on use of drugs at the primary health care level in Bangladesh. Bull World Health Organ 1994; 72: 265-71.
211. Bojalil R, Calva JJ. Antibiotic misuse in diarrhea. A household survey in a Mexican community. J Clin Epidemiol 1994; 47: 147-56.
212. Hui L, Li XS, Zeng XJ, et al. Patterns and determinants of use of antibiotics for acute respiratory tract infection in children in China. Pediatr Infect Dis J 1997; 16: 560-4.
213. Reyes H, Guiscafre H, Muñoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997; 50: 1297-304.
214. Meers PD. Infection control in developing countries. J Hosp Infect 1988; 11(Suppl A): 406-10.
215. Rasniraul L, Suthienkul O, Echevarria PD, et al. Foods as a source of enteropathogens causing childhood diarrhea in Thailand. Am J Trop Med Hyg 1988; 39: 97102.
216. Rahim Z, Aziz KM. Enterotoxigenic, hemolytic activity and antibiotic resistance of Aeromonas spp isolated from freshwater prawn marketed in Dhaka, Bangladesh. Microbiol Immunol 1994; 38: 773-8.
217. Barza M, Gorbach SL. The need to improve antimicrobial use in agriculture: ecological and human health consequences. Clin Infect Dis 2002; 34(Suppl 3): S71-144.
218. Radyowijati A, Haak H. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc Sci Med 2003; 57: 733-44.
219. Byarugaba DK. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 2004; 24: 105-10.
220. Tunger O, Karakaya Y, Cetin CB, Dinc G, Borand H. Rational antibiotic use. J Infect Dev Ctries 2009; 3: 88-93.